William Carson Buys 4,115 Shares of Annexon (NASDAQ:ANNX) Stock

Annexon, Inc. (NASDAQ:ANNX) Director William Carson acquired 4,115 shares of Annexon stock in a transaction dated Tuesday, September 30th. The stock was bought at an average price of $3.05 per share, for a total transaction of $12,550.75. Following the completion of the transaction, the director directly owned 42,060 shares of the company’s stock, valued at approximately $128,283. This represents a 10.84% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Annexon Trading Up 2.6%

NASDAQ:ANNX opened at $3.19 on Friday. Annexon, Inc. has a 12-month low of $1.28 and a 12-month high of $7.85. The firm has a market cap of $350.55 million, a price-to-earnings ratio of -2.47 and a beta of 1.36. The company’s 50-day moving average is $2.48 and its two-hundred day moving average is $2.26.

Annexon (NASDAQ:ANNX) last announced its quarterly earnings data on Thursday, August 14th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.36) by $0.02. On average, equities research analysts forecast that Annexon, Inc. will post -0.96 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Annexon

A number of hedge funds have recently made changes to their positions in the business. Millennium Management LLC raised its position in Annexon by 114.3% in the fourth quarter. Millennium Management LLC now owns 155,676 shares of the company’s stock valued at $799,000 after purchasing an additional 83,021 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new stake in shares of Annexon during the 4th quarter valued at about $252,000. California State Teachers Retirement System lifted its position in Annexon by 849.0% during the 4th quarter. California State Teachers Retirement System now owns 66,375 shares of the company’s stock worth $341,000 after acquiring an additional 59,381 shares in the last quarter. Wellington Management Group LLP boosted its holdings in Annexon by 1.8% in the 4th quarter. Wellington Management Group LLP now owns 268,166 shares of the company’s stock worth $1,376,000 after acquiring an additional 4,806 shares during the period. Finally, Hennion & Walsh Asset Management Inc. boosted its holdings in Annexon by 11.2% in the 1st quarter. Hennion & Walsh Asset Management Inc. now owns 477,567 shares of the company’s stock worth $922,000 after acquiring an additional 47,983 shares during the period.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Annexon in a research report on Saturday, September 27th. Zacks Research upgraded shares of Annexon from a “strong sell” rating to a “hold” rating in a report on Monday, August 18th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $14.00 price target on shares of Annexon in a research report on Friday, August 15th. Three analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Annexon presently has an average rating of “Hold” and a consensus target price of $12.50.

Annexon Company Profile

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.